News

Psychiatry explores extraordinary experiences like near-death experiences and out-of-body experiences, distinguishing them from mental illness to enhance patient care and understanding.

INmune Bio reveals phase 2 trial results for XPro1595, a novel treatment targeting neuroinflammation in early Alzheimer disease.

In this CME article, explore the complexities of movement disorders in psychiatric practice, including their causes, symptoms, and treatment strategies for better patient care.

Anebulo Pharmaceuticals initiates a phase 1 trial for selonabant, targeting acute cannabis toxicity in children with promising IV treatment potential.

A new study reveals tasimelteon (Hetlioz) significantly improves sleep onset in chronic insomnia patients.

Explore the challenges and strategies of deprescribing in geriatric psychiatry to enhance patient safety and reduce polypharmacy risks.

Explore the evolving understanding of autism, Tylenol use in pregnancy, and the importance of neurodiversity in today's society.

A new study reveals the overwhelming financial and emotional burdens faced by caregivers of individuals with schizophrenia, highlighting urgent support needs.

Geriatric psychiatry faces a growing demand for care. Collaborative models enhance access and improve outcomes for older adults with mental health needs.

Synendos Therapeutics reveals promising phase 1 results for SYT-510, a novel ECS modulator targeting anxiety and CNS disorders with potential for improved patient outcomes.

"Two ways of talking and living in the world.”

A phase 2 study reveals osavampator significantly reduces depression severity in adults with major depressive disorder, showing promise for treatment-resistant cases.

Younger veterans face significantly higher PTSD rates due to social challenges.

New analysis reveals Ingrezza achieves rapid symptomatic remission in tardive dyskinesia, enhancing patient quality of life and reducing disease burden.

Apathy significantly affects cognitive impairment patients, yet remains underrecognized. Discover effective assessment and treatment strategies for improved outcomes.

New phase 2a study reveals promising results for BPL-003, with a 2-dose regimen improving outcomes for patients with treatment-resistant depression.

AI chatbots rapidly integrate into daily life, raising concerns about dependency and mental health risks, paralleling the dangers of drug addiction.

Mass shootings are often misattributed to mental illness, overshadowing the real issues of grievance, radicalization, and access to weapons.

Explore innovative treatments in geriatric psychiatry, focusing on neuroplastic symptoms and emotional awareness therapy for older adults' chronic pain.

Clinicians face challenges in suicide risk assessment, especially with patients denying intent before tragic outcomes. Understanding lethal suicide deniers is crucial.

Explore the significance of moral injury in health care and its impact on trust, especially during the Jewish High Holy Days.

New phase 3 data reveals seltorexant's potential as a safer adjunctive treatment for major depressive disorder with insomnia, despite not meeting its primary end point.

Esketamine nasal spray shows significant improvement in emotional blunting for treatment-resistant depression, offering hope for affected patients.

New study shows lumateperone (Caplyta) significantly improves symptoms in major depressive disorder with anxious distress, offering hope for treatment-resistant patients.

Poetry reflections with Dr Frank Clark.

Geriatric psychiatry faces a critical shortage of specialists, impacting the mental health care of the rapidly growing older adult population.

A groundbreaking trial reveals ANK3 as a potential genetic predictor for liafensine's effectiveness in treating resistant depression.

Effective psychiatric training empowers residents to take ownership of patient care, fostering confidence and critical thinking through real-world decision-making.

In clinical practice, there are individuals who have chronic low-grade hypomanic symptoms: high energy, need for less sleep than others, chronic optimism, and chronic risk-taking.

AI chatbots may assist in mental health, but they cannot replace the essential human connection provided by psychiatrists and therapists.